vitamin k-2

Vitamin K2 (Menatetrenone) is a menaquinone compound and form of vitamin K2 with potential antineoplastic activity. Menatetrenone may act by modulating the signaling of certain tyrosine kinases, thereby affecting several transcription factors including c-myc and c-fos. This agent inhibits tumor cell growth by inducing apoptosis and cell cycle arrest.

Menaquinone-4 (Vitamin K2) is a vitamin K compound used as a hemostatic agent, and also as adjunctive therapy for the pain of osteoporosis.

Menaquinone-7 (Vitamin K2(35)) is a vitamin K2 analog, is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 (Vitamin K2(35)) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins.

Menaquinone 9 (MK-9) is a vitamin K2 analog that has been found in various bacteria, including E. coli. MK-9 is UV-sensitive and binds to soluble nitrate reductase, a component of the bacterial electron transport chain. In vivo, MK-9 increases plasma prothrombin concentration in vitamin K-deficient rats.

Menaquinone-9-D7 is a deuterated compound of Menaquinone-9. Menaquinone-9 has a CAS number of 523-39-7. Menaquinone 9 (MK-9) is a vitamin K2 analog that has been found in various bacteria, including E. coli. MK-9 is UV-sensitive and binds to soluble nitrate reductase, a component of the bacterial electron transport chain. In vivo, MK-9 increases plasma prothrombin concentration in vitamin K-deficient rats

Menaquinone-7-[13C6] (Standard) is a reference standard of Menaquinone-7-[13C6] intended for quantitative analysis, quality control, and related biochemical research applications.

2-Methylnaphthalene is used as a raw material for the production of vitamin K₃, serves as an intermediate for manufacturing vitamin K₃ in the pharmaceutical field. 2-Methylnaphthalene can be oxidized to produce β-naphthol, and is applied in long-acting or short-acting oral contraceptives.

Betrixaban maleate is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa.

PPM-18 (NSC 73233) is a potent anti-inflammatory agent that inhibits the expression of nitric oxide synthase, and also acts as an effective inhibitor of iNOS expression by blocking the binding of NF-κB to the promoter⁽¹⁾. As a vitamin K analog, this compound can also induce autophagy and apoptosis in bladder cancer cells through the ROS and AMPK signaling pathways⁽²⁾.

2-(Isopentylamino)naphthalene-1,4-dione is a vitamin K analog.1It inhibits spasms induced by pentylenetetrazole and tonic hindlimb extension induced by maximal electroshock (MES) in mice (ED50s = 349.2 and 108.1 mg/kg, respectively). It also protects mice against seizures in the 6 Hz psychomotor seizure test (ED50s = 152.7 and 263.7 mg/kg at stimulus intensities of 32 and 44 mA, respectively). 1.Li, X., Himes, R.A., Prosser, L.C., et al.Discovery of the first vitamin K analogue as a potential treatment of pharmacoresistant seizuresJ. Med. Chem.63(11)5865-5878(2020)

Betrixaban (PRT054021) is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa [1]. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [3]. Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE [2]. VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [4].

SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivative, exhibits anti-SARS-CoV-2 properties with an effective concentration (EC50) of 64.8 μM in VeroE6/TMPRSS2 cells and inhibits SARS-CoV-2 RdRp activity [1].

SARS-CoV-2-IN-66 (1), a derivative of vitamin K, serves as an inhibitor of SARS-CoV-2, with an effective concentration (EC50) of 70.8 μM in VeroE6/TMPRSS2 cells [1].